

B.R. Kotecha & Co.

CHARTERED ACCOUNTANTS

BAKULESH KOTECHA

B.Com., FCA

A/603 Siddhi,

Eastern Express Highway

Near MHADA Signal

Mulund (E), Mumbai 400 081

Mobile: 9820012065

Independent Auditor's Report

To,

The Members of Jupiter Lifeline Hospitals Limited

Report on the Consolidated Financial Statements

We have audited the accompanying consolidated financial statements of Jupiter Lifeline Hospitals Limited and its subsidiaries, which comprise the Consolidated Balance sheet as at March 31, 2020, the consolidated statement of profit and loss and the consolidated cash flow statement for the year then ended, and a summary of significant accounting policies and other explanatory information.

Management's Responsibility for the Consolidated Financial Statements

The Holding Company's Board of Directors is responsible for the preparation of these consolidated financial statements in terms of the requirements of the Companies Act, 2013 ("the Act") that give a true and fair view of the consolidated financial position, consolidated financial performance and consolidated cash flows of the Group in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial statements by the Directors of the Holding Company, as aforesaid.



Auditor's Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audit. While conducting the audit, we have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made thereunder.

We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the consolidated financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Holding Company's preparation of the consolidated financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances. But not for the purpose of expressing an opinion on whether the Holding Company has an adequate internal financial control system over financial reporting in place and the operating effectiveness of such controls. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Holding Company's Directors, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence obtained by us and the audit evidence obtained by the other auditors in terms of their reports referred to in the sub-paragraph (a) of the Other Matters paragraph below is sufficient and appropriate to provide a basis for our audit opinion on the consolidated financial statements.

Opinion

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid consolidated financial statements give the information required by the Companies Act 2013 in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the consolidated state of affairs of the Group as at March 31, 2020, and their consolidated profit and their consolidated cash flows for the year ended on that date.

Key Audit Matter

Complexities arising due to COVID-19 on the verification aspects of the financial statements have been explained in Annexure B to the audit report.

Other Matters

- (a) We did not audit the financial statements of 'Jupiter Hospital Projects Private Limited' (the Subsidiary Company), whose financial statements reflect total assets of Rs.2040.9



lakhs as at 31st March, 2020, total revenues of Rs. (0.07) lakhs and net cash flows amounting to Rs. 0.99 lakhs for the year ended on that date as considered in the consolidated financial statements. These financial statements are audited by other auditor whose reports have been furnished to us by the Management and our opinion on the consolidated financial statements, in so far as it relates to the amounts and disclosures included in respect of these subsidiary, and our report in terms of sub sections (3) and (11) of the section 143 of the Act , in so far as it relates to the aforesaid subsidiary , is based solely on the reports of the other auditor.

Our opinion on the consolidated financial statements , and our report on Other Legal and Regulatory Requirements below, is not modified in respect of the above matter with respect to our reliance on the work done and the reports of the other auditor.

Report on Other Legal and Regulatory Requirements

1. As required by Section 143 (3) of the Act, we report that:

(a) we have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit of the aforesaid consolidated financial statements..

(b) in our opinion proper books of account as required by law relating to preparation of the aforesaid consolidated financial statements have been kept by the Company so far as it appears from our examination of those books and the reports of the other auditor;

(c) the consolidated balance sheet, the consolidated statement of Profit and Loss and the consolidated cash flow statement dealt with by this Report are in agreement with the relevant books of account maintained for the purpose of preparation of the consolidated financial statements;

(d) in our opinion, the aforesaid consolidated financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014;

(e) on the basis of the written representations received from the directors of the Holding as on 31 March 2020 taken on record by the Board of Directors of the Holding Company and the reports of the statutory auditor of its subsidiary company, none of the directors of the Group companies is disqualified as on 31 March 2020 from being appointed as a director in terms of Section 164 (2) of the Act;

(f) with respect to the adequacy of the internal financial controls over financial reporting of the Group and the operating effectiveness of such controls, refer to our separate report in "Annexure A"; and

(g) with respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:



- i. the consolidated financial statements disclose the impact, if any of pending litigations on its financial position in its financial statements;
- ii. provision has been made, as required under the applicable law or accounting standards, for material foreseeable losses, if any, on long-term contracts including derivative contracts; and
- iii. There are no amounts which are required to be transferred to the Investor Education and Protection Fund by the Group.

For B. R. Kotecha & Co.

Chartered Accountants

Firm's registration number: 105283W

Bakulesh Kotecha



Bakulesh Kotecha

Proprietor

Membership number: 036309

Place: Mumbai

Date : 08/07/2020

UDIN : 20036309AAAAAN3882

JUPITER LIFELINE HOSPITALS LIMITED

Annexure-A to the Auditors' Report

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

In conjunction with our audit of the consolidated financial statements of the Company as of and for the year ended March 31, 2020, we have audited the internal financial controls over financial reporting of Jupiter Lifeline Hospitals Limited ("the Company") and its subsidiary company incorporated in India as of that date.

Management's Responsibility for Internal Financial Controls

The Board of Directors of the Company and its subsidiary company are responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India ('ICAI'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's and its subsidiary's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.



We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's and its subsidiary's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, to the best of our information and according to the explanations given to us, the Company and its subsidiary company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2020, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For **B. R. Kotecha & Co.**

Chartered Accountants

Firm's registration number: 105283W

Bakulesh Kotecha

Bakulesh Kotecha

Proprietor

Membership number: 036309

Date: 08/07/2020

UDIN: 20036309AAAAAN3882



JUPITER LIFELINE HOSPITALS LIMITED

Annexure-B to the Auditors' Report

Key Audit Matter

- Complexities arising due to COVID-19 on the verification aspects of the financial statements

It may be noted that due to COVID-19 pandemic there was lockdown and hence restriction on physical movements, social distancing, work timings, work from home, etc. Besides that the place of business was in Red Zone classification of lockdown. Hence, we were unable to visit the place of business frequently and had to rely on information digitally provided to conduct audit procedures. Audit procedures up to the period ending December 2019 were carried out in the regular course during the year by visiting place of business. Due to this, opinion expressed in this report is mainly based on the information, explanation, facts, supporting and other requirements made available to us through electronic medium by the management.

For B. R. Kotecha & Co.

Chartered Accountants

Firm's registration number: 105283W



Bakulesh Kotecha

Proprietor

Membership number: 036309

Date: 08/07/2020

UDIN: 20036309AAAAAN3882



Consolidated Balance Sheet for the period ending on 31st March 2020

Sr. No	Particulars	Note No.	31-Mar-2020 Total
I.	EQUITY AND LIABILITIES		
1	Shareholders' funds		
	(a) Share capital	1	5,087.66
	(b) Reserves and surplus	2	18,587.11
	(c) Minority Interest		0.00
	SUB TOTAL		23,674.77
2	Share application money pending allotment		-
	SUB TOTAL		
3	Non-current liabilities		
	(a) Long-term borrowings	3	24,350.54
	(b) Deferred tax liabilities (Net)	4	1,967.61
	(c) Other Long term liabilities		-
	(d) Long-term provisions		-
	SUB TOTAL		26,318.15
4	Current liabilities		
	(a) Short-term borrowings	5	1,982.75
	(b) Trade payables	6	5,859.66
	(c) Other current liabilities	7	1,186.47
	(d) Short-term provisions	8	1,271.43
	SUB TOTAL		10,300.31
	TOTAL		60,293.23
II.	ASSETS		
1	Non-current assets		
	(a) Fixed assets		
	(i) Tangible assets	9 (A)	43,408.81
	(ii) Intangible assets	9 (B)	47.05
	(iii) Capital work-in-progress	9 (C)	1,050.13
	(iv) Intangible assets under development		-
	(b) Non-current investments	10	232.61
	(c) Deferred tax assets (net)		-
	(d) Long-term loans and advances		-
	SUB TOTAL		44,738.60
2	Current assets		
	(a) Current investments		-
	(b) Inventories	11	1,396.85
	(c) Trade receivables	12	4,461.03
	(d) Cash and cash equivalents	13	697.42
	(e) Short-term loans and advances	14	2,173.13
	(f) Other current assets	15	6,826.20
	SUB TOTAL		15,554.63
	TOTAL		60,293.23
	Significant accounting policies	24	

For B. R. Kotecha & Co.
(Chartered Accountants)

B. R. Kotecha
(Proprietor)
M. NO. 036309



For and on behalf of the Board of Directors of
Jupiter Life Line Hospitals Ltd.

Dr. Ajay P. Thakker
Managing Director

Dr. Ankit Thakker
Director

Mumbai
UDIN:

20036309AAAAAN3882

Chief Financial Officer

Company Secretary

Consolidated Statement of Profit & Loss Account for the period ending on 31st March 2020

Sr No.	Particulars	Note No.	31-Mar-2020 Total
			TOTAL
	Revenue		
I.	Revenue from operations	16	46,294.52
II.	Other income	17	188.61
III.	Total Revenue (I + II)		46,483.13
	Expenses		
	Cost of materials consumed		
	Purchases of Stock-in-Trade	18	8,363.73
	Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	19	(377.17)
	Employee benefits expense	20	9,275.08
	Finance costs	21	2,568.71
	Depreciation and amortization expense	22	2,591.10
	Other expenses	23	20,772.80
	Total expenses		43,194.25
V.	Profit before exceptional and extraordinary items and tax (III-IV)		3,288.88
VI.	Exceptional items		
VII.	Profit before extraordinary items and tax (V - VI)		3,288.88
VIII.	Extraordinary Items		-
IX.	Profit before tax (VII- VIII)		3,288.88
X	Tax expense:		
	(1) Current tax		687.71
	(2) Adjustment of Earlier Years		50.37
	(3) Deferred tax		275.18
	(4) MAT Credit Entitlement		(687.71)
XI	Profit (Loss) for the period from continuing operations (IX-X)		2,963.33
XII	Profit/(loss) from discontinuing operations		-
XIII	Tax expense of discontinuing operations		-
XIV	Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)		-
XV	Profit (Loss) for the period (XI + XIV)		2,963.33
XVI	Earnings per equity share:		
	(1) Basic		5.83
	(2) Diluted		5.83

For B. R. Kotecha & Co.
(Chartered Accountants)

B. R. Kotecha
(Proprietor)
M. NO. 036309



For and on behalf of the Board of Directors of
Jupiter Life Line Hospitals Ltd.

Dr. Ajay P. Thakker
Managing Director

Dr. Ankit Thakker
Director

Mumbai
UDIN: 20036309AAAAAN3882

Chief Financial Officer

Company Secretary

Consolidated Cash Flow Statement for the period ended 31st March 2020

	31-Mar-20
A. CASH FLOW FROM OPERATING ACTIVITIES:	
Profit Before Tax	3,288.88
Adjustment for:	
Share in profits of Jupiter Pharmacy	(218.98)
Share in loss of Partnership Firms	121.52
Depreciation	2,591.10
Dividend received	(0.75)
Profit from Sale of Asset	(0.89)
Interest Income	(26.44)
Loss on Flood Assets	1,589.40
Finance Cost	2,568.71
Other Income	(43.35)
	6,580.31
Operating profit before working capital change	9,869.19
Adjusted for	
Trade and other receivable	(1,868.06)
Inventories	(376.01)
Other Current assets	(725.11)
Current Liabilities and provision	2,032.59
	(936.59)
Cash Generated from operations	8,932.60
Taxes Paid (net of refunds)	(1,461.35)
Income Tax Paid	(50.37)
Net Cash from operating activities	7,420.88
B Cash flow from Investing Activities	
Purchase of Fixed Assets	(2,859.29)
Investment in Gait Lab	1.81
Investment in Eflow Solutions	(2.00)
Investment in Katyayani Hospitality	40.00
Investment in Jupiter Pharmacy	-
Loss on Flood Assets	(1,589.40)
Investments in Corporates	(1.26)
Interest Income	26.44
Dividend Income	0.75
Other Income	44.25
Net Cash used in Investing Activities	(4,338.70)
C Cash Flow from Financing Activities	
Proceed from Call money received	-
Inflow from Short Term Loans & Advances	(1,971.62)
Maturity of Letter of credit for Import of Capital Asset	-
Proceed from Long Term Borrowings	1,804.33
Repayment Long Term Borrowings	(1,083.30)
Proceed from Short Term Borrowing	1,258.59
Proposed Dividend & Dividend distribution Tax	(613.22)
Interest Paid	(2,568.71)
Net Cash from Financing Activities	(3,173.93)
Net Increase in Cash and Cash equivalent	(91.75)
Opening Balance of Cash and Cash equivalent	789.17
Closing Balance of Cash and Cash equivalent	697.42
Net Increase in Cash and Cash equivalent	(91.75)

Notes:


1) The cash flow statement has been prepared in accordance with the requirements of Accounting Standard 3 - issued in terms of the Companies Act, 2013.

2) The figures in brackets indicate outflows of cash and cash equivalents.

3) Previous year's figures are re-grouped, re-arranged and reclassified wherever necessary.

For B. R. Kotecha & Co.
(Chartered Accountants)

B. R. Kotecha
(Proprietor)
M. NO. 036309



For and on behalf of the Board of Directors of
Jupiter Life Line Hospitals Ltd.

Dr. Ajay P. Thakker
Managing Director

Dr. Ankit Thakker
Director

Mumbai
UDIN: 20036309AAAAAN3882

Chief Financial Officer

Company Secretary


Consolidated Notes on Financial Statement for the year ended 31st March 2020

1	SHARE CAPITAL	31-Mar-2020
	Authorised Share Capital	
	60,000,000 Equity Shares of Rs.10/- each	6,000.00
	Issued, Subscribed & Paid Up	
	50,866,551 Equity Shares of Rs.10/- each fully Paid	5,086.66
		5,086.66
a	Reconciliation of the shares outstanding at the beginning and at the end of the reporting period	
		31-Mar-2020
		No. of shares
	At the beginning of the period	50,866,551
	Add: Shares Issued during the year	NIL
	Less: Shares bought back during the year	NIL
	Add: Other movements during the year	NIL
	Outstanding at the end of the period	50,866,551
b	Terms/rights attached to equity shares	
	The Company has only one class of equity shares having a face value of Rs.10 per share. Each equity shareholder's is entitled to one vote per share. The Company has not recommend any dividend for the year ended 31st March, 2020.	
d	Details of shareholders holding more than 5% shares in the Company	
		31-Mar-2020
		No. of shares
		% holding in the class
	Equity shares of Rs. 10 each fully paid up	
	Dr. Ajay P. Thakker	8,123,329
	Western Medical Solutions LLP	5,703,797
	Wisdom Wellness Pvt. Ltd.	9,800,000
	Mr. Nitin Thakker	3,120,000
		15.97%
		11.21%
		19.27%
		6.13%
	As per records of the Company viz. Register of Members, declarations received from shareholders, the said shareholding represents both legal and beneficial ownership of shares.	
e	The Company has not issued any bonus shares nor has there been any buy back of shares during five years immediately preceeding 31st March 2020.	
f	Share capital in the Subsidiary - Jupiter Hospital Projects Pvt. Ltd.	31-Mar-2020
	10,000 Equity Shares of Rs.10/- each fully Paid	1.00
		1.00
2	RESERVES AND SURPLUS	31-Mar-2020
	General Reserves	
	Balance at the beginning of the year	1,661.20
	Additional during the Year	296.34
	Balance at the end of the year	1,957.54
	Share Premium Reserve	
	Balance at the beginning of the year	1,063.87
	Additional during the Year	-
	Balance at the end of the year	1,063.87
	Surplus in the Statement of Profit & Loss	
	Balance at the beginning of the year	13,511.93
	Additional during the Year : Profit	2,963.33
	Less: Transfer to General Reserve	(296.34)
	Less: Equity Dividend (F.Y 2018-19)	(508.67)
	Less: Tax on Equity Dividend	(104.55)
	Less: Minority Interest	-
	Balance at the end of the year	15,565.70
	Total	18,587.11



Consolidated Notes on Financial Statement for the year ended 31st March 2020

3	LONG TERM BORROWING	31-Mar-2020
	Term Loans	
	Secured	
	From Banks	18,956.21
	From other than banks	-
	External Commercial Borrowing (ECB) *	5,394.33
		24,350.54
<p>i Term Loan from bank</p> <p>The Company has availed fully secured Term Loans from Axis Bank Ltd. and Siemens Bank GmbH. The facilities are secured by first pari-passu charge by way of mortgage of immovable property at Thane and Pune and Hypothecation of movable assets at Thane and Pune.</p> <p>The total Term Loans from Axis Bank is Rs.189.56 crores which includes TLII, TLIII, TLIV and TLV for Pune and Thane project.</p> <p>The balance period of repayment of TL II is 1 years, TL III is 6.6 years</p> <p>TL IV is 6 year and TL V is 10.6 years from from April, 2020</p> <p>The rate of interest on all term loan of Axis Bank Ltd. is 1 year MCLR plus 1%.</p> <p>* The Siemens Bank GmbH has disbursed ECB of Rs. 58.23 Crores for Pune and Thane project. The repayment of ECB is 6.7 Years from April, 2020. The rate of interest on ECB is Euribor plus 325 bps.</p>		
4	DEFERRED TAX LIABILITY	31-Mar-2020
	Deferred tax liability arising on account of depreciation	
	Balance at the beginning of the year	1,692.43
	Additional during the Year	275.18
	Balance at the end of the year	1,967.61
5	SHORT TERM BORROWINGS	31-Mar-2020
	Secured	
	Cash Credit and other Loan from Bank	1,045.25
	Dr. Rajesh Kasliwal	937.50
	Jupiter Life Line Hospitals Ltd.	-
		1,982.75
<p>Cash Credit and other Loan from Bank</p> <p>i The Company is having Overdraft facility from Axis Bank Ltd. of Rs. 25.00 Cr. The outstanding balance as on 31st March 2019 was Rs. 724.17 Lakhs and as on 31st March, 2020 is Rs. 1045.25 Lakhs.</p>		
6	TRADE PAYABLE	31-Mar-2020
	Sundry Creditors for Goods	2,942.72
	Sundry Creditors for Expenses **	2,121.23
		5,063.95
	Sundry Creditors for Capital Expenditure	795.71
		5,859.66



Consolidated Notes on Financial Statement for the year ended 31st March 2020

7	OTHER CURRENT LIABILITIES	31-Mar-2020
	Current Maturities of Long Term Loan	859.41
	Other (Refundable Deposit of Employee)	28.58
	Security deposit	256.83
	Interest accrued and due on borrowings	41.65
		1,186.47

- i The Repayment of Axis Bank Ltd. for Term Loan II, III, IV and V and Siemens Bank GmbH
The total repayment of Term Loans during the F.Y. 2020-21 is Rs. 859.41 Lakhs

8	SHORT TERM PROVISIONS	31-Mar-2020
	Provisions	
	Provision for Income Tax	687.71
	Provision for Expenses	318.41
	Statutory Dues	265.31
		1,271.43

10	NON CURRENT INVESTMENTS	31-Mar-2020
	Investment	
	New India Co-op Bank Ltd (50,000 Equity Shares of Rs. 10/- Each)	5.00
	The TJSB Ltd.(9,999 Equity Shares of Rs. 50/- Each)	5.00
	Jupiter Eco Energy Pvt. Ltd.(2600 shares of Rs.10 each)	0.26
	Investment in Subsidiary	
	Jupiter Hospital Projects Pvt. Ltd.(9999 shares of Rs.10 each)	1.00
	Investment in Partnership Firms	
	Investment in Partnership Firms	221.35
		232.61

Investment in Partnership Firms

Sr. no.	Name of the Partnership	Name of the Partners	Partner's Share
1	Jupiter Pharmacy	Jupiter Lifeline Hospitals Limited Mr.Rajendra Thakker	95% 5%
2	Jupiter Gait Lab	Jupiter Lifeline Hospitals Limited Dr.Taral Nagda Dr.Punita Nagda	51% 12% 37%
3	Eflow Solutions	Jupiter Lifeline Hospitals Limited Mr.Chandrashekar Reddy Dr. Ankit Thakker	75% 20% 5%
4	Katyayini Hospitality	Jupiter Lifeline Hospitals Limited Mr.Anshul Sethi	95% 5%



A TANGIBLE ASSETS

Particulars	Cost					Depreciation				Net Block	
	Opening	Additions upto	Additions after	Deletion	Total as on	As on	As on	Deletion	As on	As on	As on
	01/04/19	30/09/19	01/10/19	31/03/20	31/03/20	01/04/19	31/03/20	31/03/20	31/03/20	31/03/20	31/03/19
Land	737.05	-	-	-	737.05	-	-	-	-	737.05	737.05
Land - Pune	2,861.95	-	-	-	2,861.95	-	-	-	-	2,861.95	2,861.95
Building	21,274.55	97.43	22.16	-	21,394.15	1,993.18	328.57	-	2,321.75	19,072.40	19,281.37
Plant & Machinery	5,984.61	192.68	174.20	29.20	6,322.30	1,800.20	405.69	4.37	2,201.52	4,120.78	4,184.41
Office Equipments	228.84	11.95	9.65	-	250.43	148.18	28.02	-	176.20	74.23	80.66
Computer	481.61	33.62	38.81	10.46	543.57	376.18	61.84	7.83	430.20	113.37	105.43
Furniture & Fixtures	5,083.20	171.95	81.53	-	5,336.68	2,365.49	349.23	-	2,714.73	2,621.95	2,717.71
Furniture & Fixtures	200.87	0.66	4.55	-	206.08	156.55	17.47	-	174.02	32.06	44.32
Vehicles	269.06	-	-	-	269.07	92.52	29.07	-	121.59	147.48	176.54
Medical Equipments - 40% IT	5,525.44	5.19	1,668.22	1,350.43	5,848.42	1,611.66	378.18	100.69	1,889.14	3,959.28	3,913.78
Medical Equipments - Others	12,002.41	1,491.50	514.50	344.48	13,663.93	3,047.28	980.68	32.29	3,995.67	9,668.26	8,955.13
Total	64,649.69	2,004.98	2,513.82	1,734.67	67,433.63	11,591.24	2,578.75	145.17	14,024.82	43,408.81	43,058.35

B INTANGIBLE ASSETS

Particulars	Cost					Depreciation				Net Block	
	Opening	Additions upto	Additions after	Deletion	Total as on	As on	for the period ended	Deletion	As on	As on	As on
	01/04/19	30/09/19	01/10/19	31/03/20	31/03/20	01/04/19	31/03/20	31/03/20	31/03/20	31/03/20	31/03/19
Computer Software	88.81	29.10	1.58	-	117.49	58.09	12.35	-	70.44	47.05	28.71
Total	88.81	29.10	1.58	-	117.49	58.09	12.35	-	70.44	47.05	28.71

C CAPITAL WORK IN PROGRESS

	31-Mar-2020
	Total
CWIP as on 1/04/2019	1,150.73
Less: Net Transferred to Fixed Assets	1,873.04
Add: Additions to WIP	1,772.44
Capital Work-in-progress	1,050.13



Consolidated Notes on Financial Statement for the year ended 31st March 2020

11	INVENTORIES Closing Stock - Hospital & Hotel Stock of Consumables - Hotel	31-Mar-2020
		1,392.06
		4.79
		1,396.85
12	TRADE RECEIVABLES Sundry Debtors (Considered to be good by the Management) More than 6 Months from Invoice date Others	31-Mar-2020
		361.08
		4,099.95
		4,461.03
13	CASH AND BANK BALANCE Cash and Cash equivalents Cash on Hand Balance with Banks Current Accounts Fixed Deposit with Banks*	31-Mar-2020
		102.02
		102.02
		215.82
		379.58
		595.40
		697.42
14	SHORT TERM LOANS AND ADVANCE Unsecured, Considered Good Advance to Creditors Staff Loan Vishesh Diagnostics Pvt. Ltd.	31-Mar-2020
		110.89
		62.24
		2,000.00
		2,173.13
15	OTHER CURRENT ASSETS Prepaid Expenses Deposits MAT Credit Entitlement Tax Deducted at Source I.T. Refund Receivable Others	31-Mar-2020
		325.59
		307.46
		2,389.58
		1,461.35
		2,024.84
		317.38
		6,826.20



Consolidated Notes on Financial Statement for the year ended 31st March 2020

16	REVENUE FROM OPERATIONS	31-Mar-2020
	IP Collection	35,786.13
	OP Collection	9,390.27
	Hotel Collection	898.59
	Others	219.53
		46,294.52
17	OTHER INCOME	31-Mar-2020
	Dividend Received	0.75
	Bank Interest Received	26.44
	Share in Profit from Jupiter Pharmacy	218.98
	Share in Profit/loss of Partnership Firms	(121.52)
	Profit on Sale of Asset	0.89
	Rent Income	19.72
	Miscellaneous Income	43.35
		188.61
18	PURCHASE OF STOCK IN TRADE	31-Mar-2020
	Purchase of Stock in Trade	8,363.73
		8,363.73
19	CHANGE IN INVENTORIES OF FINISHED GOODS WORK IN PROGRESS AND STOCK IN TRADE	31-Mar-2020
	Opening Stock	1,014.89
	Closing Stock	1,392.06
		(377.17)
20	EMPLOYEE BENEFITS EXPENSES	31-Mar-2020
	Salaries, Wages, Fees and Diwali Payments	7,991.83
	Gratuity Premium	77.34
	Contribution to Provident Fund and Other Funds	445.65
	Staff Welfare	678.04
	Other Expenses	82.22
		9,275.08
21	FINANCE COST	31-Mar-2020
	Interest expenses	2,334.66
	Other borrowing costs	234.05
		2,568.71
22	DEPRECIATION AND AMORTISATION EXPENSES	31-Mar-2020
	Depreciation of tangible assets	2,578.75
	Amortization of intangible assets	12.35
		2,591.10



Consolidated Notes on Financial Statement for the year ended 31st March 2020		
23	OTHER EXPENSES	31-Mar-2020
	Rent, Rates & Taxes	573.50
	Repairs & Maintenance	492.59
	Direct Overheads	1,354.52
	Food Expenses	191.95
	Electricity Charges	1,604.44
	General Maintenance Contract Charges	635.78
	Consumables	344.46
	Printing & stationery	281.84
	Audit Fees	12.74
	Business Promotion	146.96
	Housekeeping Charges	1,500.38
	Patient Food Expenses	585.91
	Security Charges	857.82
	Professional Fees	10,551.62
	Balance W/off	342.70
	Other Expenses less than 1% of Revenue	1,118.09
	Loss due to Flood	177.50
		20,772.80
25	EARNING PER SHARES (EPS)	31-Mar-2020
	Net Profit after Tax	2,963.33
	Weighted average Number of shares	508.67
	Earning per share	5.83
	Basic & Diluted EPS	5.83
	Face Value per shares	10.00
26	EARNING IN FOREIGN CURRENCY	31-Mar-2020
	Other Income	434.05
		434.05
27	EXPENDITURE IN FOREIGN CURRENCY	31-Mar-2020
	Travelling Expenses	20.67
		20.67
28	OPERATING LEASE	
	The Company has bought computer server on lease from IBM India Pvt. Ltd. for a 36 months, payable quarterly, subject to further renewal. This Lease Rental Expenses debited to profit & loss account.	
29	PAYMENT TO AUDITORS	31-Mar-2020
	Statutory Audit	2.00
	Other Regulatory Audit	6.25
		8.25



Jupiter Life Line Hospitals Ltd.

Note 30 - Related Party Transaction

[Pursuant to Clause (h) of sub-section (3) of Section 134 of the Companies Act, 2013, and Rule 8(2) of the Companies (Accounts) Rules, 2014 – AOC-2]

Name(s) of the Related Party	Nature of Relationship	Nature of contracts/ arrangements/ transactions	Duration of contracts/arrangements/transactions	Sallient terms of the contracts or arrangements or transactions including the value, if any	Date(s) of approval with the Board, If any	Amount Paid as Advance, if any
Dr. Ajay P. Thakker	Managing Director	Remuneration	Ongoing	Remuneration	27-09-16	No
V. Raghavan	Director	Professional Fees	Ongoing	Professional Fees	27-09-16	No
Dr. Ankit Thakker	Executive Director	Remuneration	Ongoing	Remuneration	27-09-16	No
Jupiter Scan & Imaging Centre P. Ltd.	Sister Concern	Scan Charges	Ongoing	Scan Charges	24-05-15	No
Jupiter Scan & Imaging Centre P. Ltd.	Sister Concern	Rent charges	Ongoing	Rent charges	24-05-15	No
Jupiter Pharmacy	Partner	Pharmacy Purchase + Rent	Ongoing	Pharmacy Purchase	24-05-15	No
Entisi	Common Partners	Purchase	Ongoing	Purchase	12-06-19	No

Transactions during the year

Rs. In lakhs

Pharmacy Purchase	2,766.64
Purchase	42.60
Scan Charges	0.56
Rent Charges	22.50
Professional Fees	43.90
Directors Remuneration	264.35

